KIORA PHARMACEUTICALS, INC. Finite-Lived Intangible Asset, Expected Amortization, Year One
KIORA PHARMACEUTICALS, INC. (KPRX) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $25.00 thousand as of 2023-12-31, per its 10-K filed 2024-03-25.
Discontinued › Notes › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2024-03-25
- 2023-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $25.00K.
- 2022-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $25.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2023-12-31 | $25.00K 10-K · filed 2024-03-25 |
| 2022-12-31 | $25.00K 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |